Biodistribution and Cellular Internalization of Inactivated SARS-CoV-2 in Wild-Type Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Jul 2022
Historique:
received: 01 06 2022
revised: 04 07 2022
accepted: 07 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Despite the growing list of identified SARS-CoV-2 receptors, the human angiotensin-converting enzyme 2 (ACE2) is still viewed as the main cell entry receptor mediating SARS-CoV-2 internalization. It has been reported that wild-type mice, like other rodent species of the Muridae family, cannot be infected with SARS-CoV-2 due to differences in their ACE2 receptors. On the other hand, the consensus heparin-binding motif of SARS-CoV-2's spike protein, PRRAR, enables the attachment to rodent heparan sulfate proteoglycans (HSPGs), including syndecans, a transmembrane HSPG family with a well-established role in clathrin- and caveolin-independent endocytosis. As mammalian syndecans possess a relatively conserved structure, we analyzed the cellular uptake of inactivated SARS-CoV-2 particles in in vitro and in vivo mice models. Cellular studies revealed efficient uptake into murine cell lines with established syndecan-4 expression. After intravenous administration, inactivated SARS-CoV-2 was taken up by several organs in vivo and could also be detected in the brain. Internalized by various tissues, inactivated SARS-CoV-2 raised tissue TNF-α levels, especially in the heart, reflecting the onset of inflammation. Our studies on in vitro and in vivo mice models thus shed light on unknown details of SARS-CoV-2 internalization and help broaden the understanding of the molecular interactions of SARS-CoV-2.

Identifiants

pubmed: 35886958
pii: ijms23147609
doi: 10.3390/ijms23147609
pmc: PMC9316427
pii:
doi:

Substances chimiques

Heparan Sulfate Proteoglycans 0
Syndecans 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Innovative Medicines Initiative
ID : 807015
Organisme : European Union
ID : 863214
Organisme : National Research, Development and Innovation Office
ID : 2017-2.3.6-TÉT-CN-2018-00023
Organisme : National Research, Development and Innovation Office
ID : 2020-1.1.6-JÖVŐ-2021-00012

Références

Cell. 2020 Dec 10;183(6):1520-1535.e14
pubmed: 33157038
J Biol Chem. 1990 Apr 25;265(12):6884-9
pubmed: 2324102
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Mol Microbiol. 2022 Jun;117(6):1308-1316
pubmed: 35434857
Sci Rep. 2019 Feb 4;9(1):1393
pubmed: 30718543
J Virol. 2004 Jun;78(12):6567-84
pubmed: 15163749
Bioessays. 1998 Feb;20(2):156-67
pubmed: 9631661
Int J Mol Sci. 2022 Apr 20;23(9):
pubmed: 35562967
J Cell Biol. 1996 Apr;133(2):405-16
pubmed: 8609172
Lung. 2020 Dec;198(6):867-877
pubmed: 33170317
Mol Biol Cell. 2001 Feb;12(2):339-50
pubmed: 11179419
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
Int J Mol Sci. 2021 May 19;22(10):
pubmed: 34069441
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Biol Chem. 2000 Mar 31;275(13):9410-7
pubmed: 10734086
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054983
Sci Rep. 2019 Nov 12;9(1):16543
pubmed: 31719623
J Biol Chem. 2022 Mar;298(3):101710
pubmed: 35150743
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Biochim Biophys Acta. 2010 Dec;1798(12):2258-65
pubmed: 20138023
Arteriosclerosis. 1989 Jan-Feb;9(1):21-32
pubmed: 2463827
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Transbound Emerg Dis. 2021 Jul 5;:
pubmed: 34224205
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Connect Tissue Res. 2015;56(4):272-80
pubmed: 26076122
J Biophys Biochem Cytol. 1961 Dec;11:736-9
pubmed: 14474176
J Biol Chem. 2013 May 17;288(20):13988-13999
pubmed: 23525115
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207476
J Biol Chem. 2022 Feb;298(2):101507
pubmed: 34929169
Vet Q. 2021 Dec;41(1):181-201
pubmed: 33892621
Front Immunol. 2013 Dec 18;4:470
pubmed: 24391644
Chem Biol. 2005 Mar;12(3):267-77
pubmed: 15797210
Int J Mol Sci. 2021 Jan 20;22(3):
pubmed: 33498183
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Circ Res. 2005 Mar 18;96(5):488-500
pubmed: 15774861
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
Front Microbiol. 2021 Aug 31;12:626553
pubmed: 34531831
J Histochem Cytochem. 2021 Feb;69(2):93-104
pubmed: 32757871
Adv Drug Deliv Rev. 2007 Aug 10;59(8):748-58
pubmed: 17659804
Mol Ther. 2004 Dec;10(6):1011-22
pubmed: 15564133
Comput Struct Biotechnol J. 2021;19:2806-2818
pubmed: 33968333
Matrix Biol. 2014 Apr;35:51-5
pubmed: 24145152
Front Plant Sci. 2020 Jul 07;11:1006
pubmed: 32733513
Biochem J. 2000 Nov 1;351 Pt 3:607-12
pubmed: 11042114
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21690215
Angew Chem Int Ed Engl. 2002 Feb 1;41(3):391-412
pubmed: 12491369
Cells. 2021 Jul 17;10(7):
pubmed: 34359983
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
J Infect Public Health. 2021 Jul;14(7):910-921
pubmed: 34119845
Front Public Health. 2021 Jan 11;8:567395
pubmed: 33505949
Viruses. 2019 Jul 01;11(7):
pubmed: 31266258
Int J Exp Pathol. 2015 Feb;96(1):1-10
pubmed: 25546317
J Biol Chem. 1999 Sep 3;274(36):25718-25
pubmed: 10464309
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2020 Mar 6;367(6482):
pubmed: 32139519
Antiviral Res. 2020 Sep;181:104873
pubmed: 32653452
Biochemistry. 2007 Jan 16;46(2):492-501
pubmed: 17209559
J Virol. 2001 Oct;75(19):9187-200
pubmed: 11533182
J Allergy Clin Immunol. 2020 Jul;146(1):18-22
pubmed: 32389590

Auteurs

Anett Hudák (A)

Pharmacoidea Ltd., H-6726 Szeged, Hungary.

Gareth Morgan (G)

Boeckeler Instruments, Inc., Tucson, AZ 85714, USA.

Jaromir Bacovsky (J)

Delong Instruments a.s., 612 00 Brno, Czech Republic.

Roland Patai (R)

Institute of Biophysics, Biological Research Centre, H-6726 Szeged, Hungary.

Tamás F Polgár (TF)

Institute of Biophysics, Biological Research Centre, H-6726 Szeged, Hungary.
Theoretical Medicine Doctoral School, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary.

Annamária Letoha (A)

Department of Medicine, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary.

Aladar Pettko-Szandtner (A)

Laboratory of Proteomics Research, Biological Research Centre, H-6726 Szeged, Hungary.

Csaba Vizler (C)

Institute of Biochemistry, Biological Research Centre, H-6726 Szeged, Hungary.

László Szilák (L)

Pharmacoidea Ltd., H-6726 Szeged, Hungary.

Tamás Letoha (T)

Pharmacoidea Ltd., H-6726 Szeged, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH